Vistagen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. on June 16, 2026. The report addresses corporate governance changes regarding the Board of Directors ahead of the 2026 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of two directors from the Board of Directors:
- Ms. Margaret FitzPatrick: Notified the Company on June 16, 2026, of her decision not to stand for re-election.
- Dr. Joanne Curley: Notified the Company on June 17, 2026, of her decision not to stand for re-election.
Both directors will continue to serve until the conclusion of their terms at the 2026 Annual Meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The report is limited to the disclosure of the directors' decisions regarding re-election.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the 2026 Annual Meeting.
- Confirm if the Company has announced candidates to replace Ms. FitzPatrick and Dr. Curley.
- Review the Company's proxy statement for the 2026 Annual Meeting for details on the election process.